Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $165 from $166 and keeps an Overweight rating on the shares. The firm, which sees several factors that should lead to a stronger Q2 after a “meaningful miss” on revenue in Q1, sees Jazz as likely entering a key inflection point in the second half with major clinical catalysts, the analyst tells investors in a preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Positive Outlook for Jazz Pharmaceuticals Amidst Anticipated Recovery and Growth
- Jazz Pharmaceuticals’ Phase 4 Study on Epidiolex: A Potential Game-Changer for Tuberous Sclerosis Complex
- Jazz Pharmaceuticals’ Promising Study on Zanidatamab for Breast Cancer
- Jazz Pharmaceuticals’ XYWAV Study: A Potential Game-Changer for Sleep Disorders
- Jazz Pharmaceuticals’ Zanidatamab Study: A Potential Game-Changer in Breast Cancer Treatment?